Newest studies

Advancing dementia identification using machine learning and real‐world sequential health data

53/100 ✓ Peer-reviewed Digital health tools Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring

Key finding: The best-performing model achieved an area under the curve of 0.86 (95% confidence interval [CI]: 0.84-0.87), with sensitivity of 73.3% (95% CI: 72.3-74.2) and specificity of 87.5% (95% CI: 86.7-88.2). +4 more findings

• Digital Tools

Full summary, score breakdown and related studies → Original source

Stigma, isolation, and depression in Chinese and Korean American dementia caregivers

43/100 ✓ Peer-reviewed Caregiving Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring

Key finding: These findings identify affiliate stigma as an important risk factor for dementia caregivers’ depressive symptoms, operating through both objective and emotional forms of social disconnection. +1 more finding

• Caregiving

Full summary, score breakdown and related studies → Original source

Amyloid- und Tau-PET im Real-World-Setting: Vergleich von visueller Beurteilung und Quantifizierung mit Liquor-Biomarkern zur Optimierung der Alzheimer-Diagnostik

32/100 ✓ Peer-reviewed Brain scans and imaging Nuklearmedizin - NuclearMedicine

Key finding: Sowohl in der Tau- als auch in der Amyloid-PET-Bildgebung zeigte die Quantifizierung eine gute bis exzellente Vorhersage der visuellen Beurteilung (Tau: AUC=0,86, p<0,0001; Amyloid: AUC=0,99, p<0,0001). +4 more findings

• Brain Scans

Full summary, score breakdown and related studies → Original source

Cyclic 2.5D Perceptual Loss for Cross‐Modal 3D Medical Image Synthesis: T1w MRI to Tau PET

34/100 ✓ Peer-reviewed Brain scans and imaging Human Brain Mapping

Key finding: Positron emission tomography (PET) provides an in vivo molecular marker for various diseases, including Alzheimer's disease and related dementias (ADRD). +4 more findings

• Brain Scans
• Policy

Full summary, score breakdown and related studies → Original source

Vergleich kinetischer [¹⁸F]PI-2620 Tau-PET Parameter zum longitudinalen Monitoring der Alzheimer-Erkrankung

31/100 ✓ Peer-reviewed Brain scans and imaging Nuklearmedizin - NuclearMedicine

Key finding: 5/15 Patient:innen zeigten initial einen visuell negativen Tau-PET Scan zur Baseline, davon konvertierten vier im Follow-up zu einem Tau-positiven Befund. +4 more findings

• Brain Scans

Full summary, score breakdown and related studies → Original source

Decoupling Alzheimer Disease Pathologic Abnormalities at PET with Improved Clinical Relevance by Interpretable Adversarial Decomposition Learning

53/100 ✓ Peer-reviewed Brain scans and imaging Radiology

Key finding: Pathophysiologic-constrained ADL provided interpretable, personalized pathologic maps and an AI-derived ADAD score that more closely linked PET pathologic abnormalities with multimodal clinical measures. © RSNA, 2026 +2 more findings

• Brain Scans
• Biomarkers
• Brain Biology

Full summary, score breakdown and related studies → Original source

Converting short cognitive screen scores: Comparing the Quick mild cognitive impairment screen, Montreal cognitive assessment, and Mini-mental state examination

39/100 ✓ Peer-reviewed Getting a diagnosis Journal of Alzheimer s Disease Reports

Key finding: This study provides validated conversion tables between the Q mci screen and two widely-used cognitive instruments, to support the use of the Q mci screen in research (facilitating cross-instrument comparability and harmonization across studies), and clinical settings (determining eligibility for disease-modifying therapies). +1 more finding

• Diagnosis
• Early Stage

Full summary, score breakdown and related studies → Original source

Dementia in Severe Schizophrenia

59/100 ✓ Peer-reviewed Getting a diagnosis JAMA Psychiatry

Key finding: In this study's cohort of 155 individuals with SETRS (mean [SD] age, 59.3 [10.3] years; 56 female participants [36.1%]), 153 of 155 (98.7%) scored below the cutoff of 26 for mild cognitive impairment, and 73 of 155 (47.1%) scored below the cutoff of 10 for severe dementia (mean [SD] MoCA score, 9.8 [6.4]). +4 more findings

Full summary, score breakdown and related studies → Original source

Divergent patterns of cognitive decline in preclinical Alzheimer's disease: Implications for secondary prevention trials

50/100 ✓ Peer-reviewed Treatments Alzheimer s & Dementia

Key finding: Three trajectory classes were identified: stable, slow decliners, and fast decliners. +3 more findings

• Early Stage
• Prevention

Full summary, score breakdown and related studies → Original source

“Doctor, if it were you, which would you choose?”: Navigating personal preference questions in anti‐amyloid immunotherapy selection

29/100 ✓ Peer-reviewed Treatments Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring

Key finding: The approval of lecanemab and donanemab represents a watershed moment in Alzheimer Disease (AD) treatment, yet clinicians face a novel challenge: guiding patients through treatment selection when head-to-head comparative data are absent. +2 more findings

• Treatments

Full summary, score breakdown and related studies → Original source

Bildgebungsanomalien bei Alzheimer-Therapie mit Lecanemab

26/100 ✓ Peer-reviewed Treatments Neuroradiologie Scan

Key finding: Sie hoffen, dass dieser Bildgebungsmarker zukünftig bei der Risikostratifizierung sowie bei Therapieentscheidungen helfen kann. +4 more findings

• Treatments

Full summary, score breakdown and related studies → Original source

Cost-Effectiveness of Donanemab for Early Alzheimer Disease in Australia

32/100 ✓ Peer-reviewed Treatments Deakin Research Online (Deakin University)

Key finding: Donanemab increased total healthcare costs ($300,689 vs. $178,121) and societal costs ($389,113 vs. $283,618) compared with standard care per capita, while improving health outcomes (4.38 vs. 4.01 QALYs) per capita. +4 more findings

• Treatments
• Policy
• Health Equity

Full summary, score breakdown and related studies → Original source

TGF-β Pathway–Based Polygenic Risk Score Modifies the Association between Red Meat Intake and Colorectal Cancer Risk: Application of a Novel Pathway-Based PRS Method

47/100 ✓ Peer-reviewed Genetics Cancer Epidemiology Biomarkers & Prevention

Key finding: A total of 30 variants were overrepresented in four pathways: presenilin/Alzheimer disease, cadherin/WNT signaling, gonadotropin-releasing hormone receptor, and transforming growth factor-β (TGF-β) signaling. +4 more findings

• Genetics

Full summary, score breakdown and related studies → Original source

The association between major depressive disorder, plasma biomarkers of Alzheimer's disease, and mild behavioral impairment among older adults

33/100 ✓ Peer-reviewed Risk factors Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring

Key finding: Older adults with MDD were more likely to endorse MBI. +3 more findings

• Biomarkers

Full summary, score breakdown and related studies → Original source

84 Effect of the 2020 CMS telehealth expansion on diagnostic prevalence of Alzheimer’s disease and related dementias

32/100 ✓ Peer-reviewed Risk factors Journal of Clinical and Translational Science

Key finding: This reduction is likely a consequence of the COVID-19 pandemic, which may have decreased overall diagnostic opportunities. +2 more findings

• Diagnosis
• Digital Tools
• Policy

Full summary, score breakdown and related studies → Original source

Incidence of amyloid-related imaging abnormalities and health resource utilization in patients with Alzheimer disease receiving monoclonal antibody treatments: A real-world evidence study

39/100 ✓ Peer-reviewed Drug development Journal of managed care & specialty pharmacy

Key finding: All recently approved monoclonal antibodies (eg, aducanumab, lecanemab, and donanemab) for Alzheimer disease (AD) were shown to increase the risks of amyloid-related imaging abnormalities (ARIA) in randomized clinical trials, which can include brain swelling or hemorrhage. +3 more findings

• Treatments
• Side Effects
• Brain Scans

Full summary, score breakdown and related studies → Original source

Abnormalities in core AD biomarkers precede inflammatory and glial markers in CSF in Autosomal Dominant Alzheimer’s Disease

16/100 ⚠ Preprint — not yet peer-reviewed Tau biomarkers medRxiv

Key finding: Increasing evidence suggests that accurate prediction of Alzheimer’s disease (AD) symptom onset requires more than amyloid- and tau-centric biomarkers such as cerebrospinal fluid (CSF) Aβ42/40, total tau and p-tau181 and plasma p-tau217. +3 more findings

• Biomarkers
• Genetics

Scored 28 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

Full summary, score breakdown and related studies → Original source

Low-Dose Lithium for Mild Cognitive Impairment: A Pilot Randomized Clinical Trial

72/100 ✓ Peer-reviewed Treatments JAMA neurology

Key finding: Among 80 participants (mean [SD] age, lithium: 72.93 [8.77] years; placebo: 71.22 [6.47] years; 56% female), none of the 6 coprimary outcomes met the prespecified significance threshold. +1 more finding

• Clinical Trials

Full summary, score breakdown and related studies → Original source

Utilization and Lifetime Costs of Formal Care for Alzheimer's Disease Dementia in Sweden

56/100 ✓ Peer-reviewed Costs and economics PharmacoEconomics

Key finding: This study estimated the utilization and lifetime costs of formal care for AD dementia using longitudinal register data. +3 more findings

• Policy

Full summary, score breakdown and related studies → Original source

Increase in healthcare utilization and Medicare payment with progression of preclinical Alzheimer's disease

50/100 ✓ Peer-reviewed Costs and economics Journal of Prevention of Alzheimer's Disease

Key finding: HRU and payments were overall similar between A4 and LEARN Medicare. +4 more findings

• Policy
• Early Stage

Full summary, score breakdown and related studies → Original source

Sex Differences in Amyloid Pathology by Race, Ancestry, and Apolipoprotein E ε4 in an Admixed Autopsy Sample

63/100 ✓ Peer-reviewed Genetics JAMA neurology

Key finding: Female individuals had higher plaque burden than male individuals (unadjusted odds ratio [OR], 1.97; 95% CI, 1.67-2.29; P Conclusions and relevance The findings indicate that female sex, APOEε4, and both race and African ancestry were jointly associated with amyloid in this study population. +2 more findings

• Genetics
• Brain Biology

Full summary, score breakdown and related studies → Original source

Cost-Effectiveness of Donanemab for Early Alzheimer Disease in Australia

45/100 ✓ Peer-reviewed Costs and economics The Medical journal of Australia

Key finding: Donanemab provides clinical benefits but is unlikely to be cost-effective under current Australian thresholds. +2 more findings

• Policy
• Treatments
• Brain Scans

Full summary, score breakdown and related studies → Original source

Sex Differences in P-Tau217, Tau Aggregation, and Cognitive Decline

68/100 ✓ Peer-reviewed Biomarkers JAMA neurology

Key finding: These findings add to growing evidence that women have a differential tau response to Aβ that may emerge at the point of p-tau secretion. +4 more findings

• Biomarkers
• Brain Biology

Full summary, score breakdown and related studies → Original source

Integration of plasma eMTBR-tau243 and p-tau217 in the diagnosis and stratification of Alzheimer's disease: a prospective cohort study

72/100 ✓ Peer-reviewed Biomarkers The Lancet. Neurology

Key finding: In this prospective cohort study, we included adults aged 40 years or older with subjective cognitive decline, mild cognitive impairment, or dementia, based on cognitive test results and clinical assessments, consecutively recruited at two memory clinics in Sweden, as part of the Swedish BioFINDER-2 study. +2 more findings

• Biomarkers
• Diagnosis
• Early Stage

Full summary, score breakdown and related studies → Original source

Digital Reminiscence for Predeath Grief Among Family Caregivers of Patients With Dementia: A Pilot Randomized Clinical Trial

65/100 ✓ Peer-reviewed Caregiving JAMA Network Open

Key finding: This pilot randomized clinical trial demonstrated the feasibility, acceptability, and preliminary efficacy of LMH-4-DCP in reducing caregiver grief, with improvements in caregiver-care recipient relationship quality. +4 more findings

• Clinical Trials
• Caregiving

Full summary, score breakdown and related studies → Original source